Neurologian yksikkö
Department of Neurology

Julkaisut 1996
Publications 1996

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Björklund M et al. An indirect cholinesterase inhibitor, metrifonate, increases neocortical EEG arousal in rats.
2 Björklund M et al. Alpha2c-adrenoceptor overexpressing mice as a model to study cognitive functions of alpha2-adrenoceptors.
3 Blennow K et al. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.
4 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
5 Diener HC et al. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
6 European Carotid Surgery Trialists` Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC european carotid surgery trial.
7 Fogelholm R et al. Factors delaying hospital admission after acute stroke.
8 Grobbee DE et al. Incidence and risk factors of ischaemic and haemorrhagic stroke in Europe.
9 Gulyás AI, Freund TF. Pyramidal cell dendrites are the primary targets of calbindin D28k-immunoreaktive interneurons in the hippocampus.
10 Hansson G et al. Intact brain serotonin system in vascular dementia.
11 Helenius M et al. Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappaB.
12 Helenius M et al. Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle.
13 Helisalmi S et al. Apolipoprotein E polymorphism in patients with different neurodegenerative disorders.
14 Helisalmi S et al. Screening for amyloid beta precursor protein codon 665, 670/671 and 717 mutations in Finnish patients with Alzheimer's disease.
15 Helkala E-L et al. Slow-wave activity in the spectral analysis of the electroencephalogram and volumes of hippocampus in subgroups of Alzheimer`s disease patiens.
16 Helkala E-L et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study.
17 Huovila A-PJ et al. ADAMs and cell fusion.
18 Hänninen T. Age-associated Memory Impairment. A Neuropsychological and Epidemiological Study.
19 Hänninen T et al. Prevalence of ageing-associated cognitive decline in an elderly population.
20 Jakovljevic D et al. Seasonal variation in the occurrence of stroke in a Finnish adult population. The FINMONICA stroke register.
21 Jolkkonen J et al. Seizure-induced damage to the hippocampus is prevented by modulation of the GABAergic system.
22 Jäkälä P et al. The effects of cholinergic drugs on rat neocortical high-voltage spindles in ketanserin-treated rats.
23 Jäkälä P et al. Suppression of neocortical high-voltage spindles by nicotinic acetylcholine and 5-HT2 receptor stimulation.
24 Jäkälä P et al. Effects of combined nimodipine and metrifonate on rat cognition and cortical EEG.
25 Kiviranta T et al. Vasopressin in the cerebrospinal fluid of febrile children with or without seizures.
26 Kosunen O. A Neuropathologic Study on Alzheimer's Disease with a Special Emphasis on Diagnostic Accuracy.
27 Kosunen O et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study.
28 Kotti T et al. The calretinin-containing mossy cells survive excitotoxic insult in the gerbil dentate gyrus. Comparison of excitotoxicity-induced neuropathological changes in the gerbil and rat.
29 Kälviäinen R et al. Cognitive adverse effects of antiepileptic drugs. Incidence, mechanisms and therapeutic implications.
30 Laakso M. MRI of Hippocampus in Incipient Alzheimer`s Disease.
31 Laakso MP et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study.
32 Laakso MP et al. MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment.
33 Lahtinen H et al. Failure of carbamazepine to prevent behavioural and histopathological sequels of experimentally induced status epilepticus.
34 Lehtinen SK et al. Down-regulation of transcription factors AP-1, Sp-1, and NF-kappaB precedes myocyte differentation.
35 Lehtinen SK et al. Down-regulation of nuclear binding activities of OXBOX-REBOX transcription factors during cellular senescence.
36 Lehtovirta M. Familial Alzheimer's Disease. A Clinical and Molecular Genetic Study.
37 Lehtovirta M et al. Spectral analysis of EEG in Alzheimer's disease: relation to apolipoprotein E polymorphism.
38 Lehtovirta M et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism.
39 Lehtovirta M et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon4 allele.
40 Miettinen M et al. Coexistence of parvalbumin and GABA in nonpyramidal neurons of the rat entorhinal cortex.
41 Murros K. The cranial nerves:anatomy, imaging, vascularisation.
42 Paddock-Eliasziw LM et al. Long-term prognosis and the effect of carotid endarterectomy in patients with recurrent ipsilateral ischemic events.
43 Partanen J et al. EEG reactivity correlates with neuropsychological test scores in Down's syndrome.
44 Petit D et al. Electrophysiological tests.
45 Pirttilä T et al. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease.
46 Pirttilä T et al. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls.
47 Pitkänen A. Treatment with antiepileptic drugs: Possible neuroprotective effects.
48 Pitkänen A et al. Severity of hippocampal atrophy correlates with the prolongation of MRI T2 relaxation time in temporal lobe epilepsy but not in Alzheimer's disease.
49 Pitkänen A et al. Vigabatrin and carbamazepine have different efficacies in the prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala.
50 Puumala T et al. Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder.
51 Puumala T et al. Effects of St-587 and prazosin on water maze and passive avoidance performance of scopolamine-treated rats.
52 Reeben M et al. Induced expression of neurotrophins in transgenic mice overexpressing ornithine decarboxylase and overproducing putrescine.
53 Reeben M et al. The effects of noradrenergic lesion and alfa2-adrenergic drugs on nerve growth factor and brain-derived neurotrophic factor mRNA expression in the rat hippocampus and peripheral tissues.
54 Reinikainen K. Neurofarmakologia ja dementia.
55 Riekkinen M et al. Depletion of serotonin, dopamine and noradrenaline in aged rats decreases the therapeutic effect of nicotine, but not of tetrahydroaminoacridine.
56 Riekkinen M et al. Effects of combined block of alfa1-adrenoceptors and NMDA receptors on spatial and passive avoidance behavior in rats.
57 Riekkinen P Jr. Can animal models predict the clinical response of new therapies in Alzheimer`s disease?
58 Riekkinen P Jr et al. Effects of Alzene and tacrine on water maze reference and working memory function in medial septal-lesioned rats.
59 Riekkinen P Jr et al. Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats.
60 Riekkinen PJ Sr et al. Rationale to treat Alzheimer's disease with selegiline - can we prevent the progression of the disease?
61 Salmenperä T et al. Cost of epilepsy: review of the literature.
62 Salonen T et al., ed. 20 Years of Brain Research in Kuopio.
63 Savander V et al. Intrinsic connections of the rat amygdaloid complex: projections originating in the accessory basal nucleus.
64 Savander V et al. Topographic projections from the periamygdaloid cortex to select subregions of the lateral nucleus of the amygdala in the rat.
65 Sivenius J. Appropriate use of antiplatelet therapy in TIA and stroke patients.
66 Sivenius J et al. Upcoming alternatives to aspirin for antiaggregant therapy in stroke prevention.
67 Soininen H. Apolipoprotein E epsilon4 allele - a risk factor for Alzheimer`s disease and hippocampal volume loss.
68 Soininen H. ApoE and Alzheimer`s disease-neuropathological, MRI and polpulation-based studies.
69 Soininen HS et al. ApoE genotype and MRI volumetry: implication for therapy.
70 Soininen HS, Riekkinen PJ Sr. Apolipoprotein E, memory and Alzheimer's disease.
71 Sorvari H et al. Parvalbumin-immunoreactive neurons make inhibitory synapses on pyramidal cells in the human amygdala: a light and electron microscopic study.
72 Sorvari H et al. Calretinin-immunoreactive cells and fibers in the human amygdaloid complex.
73 Sorvari H et al. Calbindin-D28K-immunoreactive cells and fibres in the human amygdaloid complex.
74 Suomen muistitutkimusyksiköiden asiantuntijaryhmä. Muistihäiriöt ja dementia.
75 Tanila H. Leikkaus, joka vei muistin.
76 Tuomilehto J et al. Ten-year trends in stroke incidence and mortality in the FINMONICA stroke study.
77 Tuunanen J et al. Status epilepticus causes selective regional damage and loss of GABAergic neurons in the rat amygdaloid complex.
78 Vanhanen M et al. ERPs reveal deficits in automatic cerebral stimulus processing in patients with NIDDM.
79 Vanninen E et al. Frequency of carotid endarterectomy-related subclinical cerebral complications.
80 Yavich L et al. The systemic administration of tacrine or selegiline facilitate spatial learning in aged fisher 344 rats.
81 Åkerman KK et al. Analysis of low-dose benzodiatzepines by HPLC with automated solid-phase extraction.

Neurologian yksikkö Department of Neurology
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008